Claims for Patent: 7,329,725

Summary for Patent: 7,329,725

Title:	Phage displayed Trp cage ligands
Abstract:	Trp cage binding domain polypeptides are disclosed. The Trp cage binding domains have the generic formulas of SEQ ID NO: 2, 7, 10 or 11. They can be efficiently produced and screened using phage display technology.
Inventor(s):	Quay; Steven C. (Edmonds, WA), Badders; Douglas L. (Seattle, WA), Herman; Richard E. (Redmond, WA), Houston, Jr.; Michael E. (Sammamish, WA), Johnson; Paul Hickok (Snohomish, WA)
Assignee:	Nastech Pharmaceutical Company Inc. (Bothell, WA)
Application Number:	10/976,942
Patent Claims:	1. An isolated polypeptide comprising the amino acid sequence SEQ ID NO: 11, wherein said polypeptide comprises a tryptophan cage domain. 2. The polypeptide of claim 1, wherein said polypeptide consists of 23 amino acids. 3. The polypeptide of claim 1, wherein said polypeptide further comprises in operable combination: a first amino acid sequence directing the display of the polypeptide on the surface of a lytic phage; and optionally a second amino acid sequence that targets the polypeptide to the inner membrane of a cell. 4. The polypeptide of claim 3, wherein the first amino acid sequence is a lytic phage coat protein or fragment thereof. 5. The polypeptide of claim 1, wherein said polypeptide is displayed on the surface of a lytic bacteriophage. 6. The polypeptide of claim 5, wherein the bacteriophage is T7. 7. The polypeptide of claim 1, wherein said polypeptide is folded into a Trp cage domain conformation. 8. An isolated polypeptide comprising the amino acid sequence SEQ ID NO: 11, wherein said polypeptide is produced from a nucleic acid comprising the sequence SEQ ID NO: 12; wherein K is guanine or thymine, and N is any nucleotide. 9. The polypeptide of claim 8, wherein K is guanine. 10. The polypeptide of claim 8, wherein said polypeptide is propagated in a bacterium via lytic bacteriophage. 11. The polypeptide of claim 10, wherein the bacterium is Escherichia coli. 12. A fusion protein consisting of (a) the Trp-cage binding domain SEQ ID NO:11 and (b) a carboxy terminal carrier protein moiety of a viral protein of a lytic phage, said fusion protein optionally including (c) a flexible linker between said amino and carboxy terminal moieties, said carrier protein moiety acting, when the fusion protein is produced in a host cell infected by the lytic phage, to cause the display of the fusion protein or a processed form thereof on the surface of lytic phage particles. 13. The fusion protein of claim 12 wherein the carboxy terminal moiety is a portion of a T7 bacteriophage protein. 14. The fusion protein of claim 12 wherein the carrier protein moiety corresponds to a 10-b T7 viral protein of T7. 15. A fusion protein comprising (a) a carrier protein moiety corresponding to a 10-b protein of a T7 phage, said carrier protein moiety acting, when the fusion protein is produced in a host cell infected by T7 phage, to cause the display of the fusion protein or a processed form thereof on the surface of the phage, and (b) a Trp cage binding domain attached to the amino terminus of said carrier protein moiety, wherein the Trp cage binding domain is a polypeptide comprising the amino acid sequence SEQ ID NO: 11. 16. A lytic phage particle bearing a fusion protein according to claim 12. 17. A library of lytic phage comprising Trp cage fusion protein-bearing phage according to claim 16 collectively displaying a plurality of Trp cage binding domains. 18. A lytic phage bearing on its outer surface a chimeric Trp cage binding protein, said protein comprising (i) the Trp cage binding domain SEQ ID NO: 11, and at least a functional portion of a coat protein of said phage, said portion acting, when the chimeric protein is produced in a suitable host cell, to cause the display of the chimeric Trp cage binding protein or a processed form thereof on the outer surface of the phage. 19. The lytic phage of claim 18 wherein the phage is a T7 phage. 20. The lytic phage of claim 18 wherein the coat protein is a T7 phage protein. 21. The lytic phage of claim 20 wherein the coat protein is the T7 10-b protein. 22. The lytic phage of claim 18 wherein the chimeric protein further comprises a flexible linker, linking said Trp cage binding domain to said portion of coat protein, which is specifically cleavable by a site-specific protease. 23. The lytic phage of claim 22 wherein the site-specific protease is Factor Xa, Factor XIa, Kallikvein, thrombin, Factor XIIa, collagenase or enterokinase. 24. The lytic phage of claim 18, said phage further bearing on its outer surface the corresponding wild-type coat protein of said phage. 25. The lytic phage of claim 18 wherein the Trp cage binding domain is coupled to the amino terminus of the processed coat protein. 26. A library of lytic phage displaying Trp cage binding domains comprising the amino acid sequence SEQ ID NO: 11. 27. A method for obtaining a nucleic acid encoding a Trp cage binding domain comprising: a) preparing a variegated population of lytic phage, each phage including a nucleic acid construct coding for a chimeric Trp cage binding protein, each said construct comprising DNA encoding (i) a Trp cage binding domain of the amino acid sequence SEQ ID NO: 11, and (ii) an outer surface transport signal for obtaining the display of the Trp cage binding domain on the outer surface of the phage, wherein said variegated population of phage collectively display a plurality of different Trp cage binding domains, the differentiation among said plurality of different Trp cage binding domains occurring through the random variation of one or more of the seven Xaa amino acid positions of SEQ ID NO: 11; b) causing the expression of said chimeric Trp cage binding proteins and the display of said Trp cage binding domains on the outer surfaces of said phage; c) contacting said population of phage with a target material such that said Trp cage binding domains and the target material interact; d) separating phage displaying a Trp cage binding domain that binds the target material from phage that do not so bind, and e) recovering at least one phage displaying on its outer surface a chimeric Trp cage binding protein comprising a Trp cage binding domain, said phage enclosing said DNA encoding the Trp cage binding domain. 28. The method of claim 27 wherein said phage are amplifiable in cell culture.

Details for Patent 7,329,725

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2023-10-29